NEW YORK (GenomeWeb) – Last week, NanoString Technologies provided the first details on its companion diagnostic for Merck's anti-PD-1 drug pembrolizumab (Keytruda), a gene expression assay looking at 18 markers for immune system response to a tumor.

On a conference call following the release of the Seattle-based firm's second quarter financial results, NanoString CEO Brad Gray introduced the "Tumor Inflammation Signature" assay.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

York University researchers find genomic evidence of inbreeding in the yellow-banded bumblebee, according to Reuters.

In its survey of US adults, the Pew Research Center finds that views on the genetic engineering of animals depend on why it's done.

The Scientist reports agricultural researchers are working on a gene-stacking tool.

In Nature this week: statistical method for overcoming case-control imbalance issues, and more.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
12
Sponsored by
Qiagen

This webinar will discuss ongoing work to apply T-cell receptor sequencing (TCRseq) approaches to immunotherapy monitoring for melanoma patients.